<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00484900</url>
  </required_header>
  <id_info>
    <org_study_id>2005/57/01</org_study_id>
    <nct_id>NCT00484900</nct_id>
  </id_info>
  <brief_title>Multi-Centre Trial Comparing Three Artemisinin-Based Combination Treatments on P. Falciparum Malaria</brief_title>
  <official_title>Open Randomized Multi-Centre Trial, Comparing Artesunate-Sulfamethoxypyrazine-Pyrimethamine FDC Over 3 Days, Artesunate-Sulfamethoxypyrazine-Pyrimethamine FDC Over 48 Hours and Artemether-Lumefantrine FDC Over 3 Days on P. Falciparum Malaria</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dafra Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dafra Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this open randomised multi-centre clinical trial is to test the hypothesis
      that three pills of the fixed dose combination artesunate/sulfamethoxypyrazine/pyrimethamine,
      administered over 24 hours is not inferior in efficacy to the same drug administered over 48
      hours and that the fixed dose combination artesunate/sulfamethoxypyrazine/pyrimethamine
      As/SMP fdc, independently of the duration of its dose interval, is not inferior in efficacy
      to 6 - 24 pills (number of pills administered to respectively children and adults)of the 60
      hours treatment of artemether/lumefantrine for the treatment of uncomplicated P. falciparum
      malaria.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2006</start_date>
  <completion_date type="Actual">May 2007</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PCR corrected Adequate Clinical and Parasitological Response</measure>
    <time_frame>on day 28 (follow-up period)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Early treatment failure</measure>
    <time_frame>between day 0 and day 3</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Late clinical failure</measure>
    <time_frame>between day 4 and day 28</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Late parasitological failure</measure>
    <time_frame>between day 7 and day 28</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Parasitic clearance</measure>
    <time_frame>28 day follow-up period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fever clearance</measure>
    <time_frame>28 day follow-up period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parasitological re-infection</measure>
    <time_frame>28 day follow-up period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gametocyte carriage</measure>
    <time_frame>28 day follow-up period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety - Adverse events</measure>
    <time_frame>28 day follow-up period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Haemoglobin levels</measure>
    <time_frame>28 day follow-up period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical and biological tolerance (Haemogram + Lever tests)</measure>
    <time_frame>28 day follow-up period</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">1390</enrollment>
  <condition>Plasmodium Falciparum Malaria</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Co-Arinate FDC</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Coartem</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age at least 6 months,

          -  weight at least 5 kg,

          -  residing in one of the four countries (Mali, Cameroon, Sudan, Rwanda),

          -  able to receive oral treatment,

          -  having an axillary body temperature of more than 37,5 degrees Celsius or history of
             fever within the proceeding 24 hours,

          -  suffering from a mono specific P. falciparum infection with a parasite density between
             2000 and 200000 asexual forms per micro litre of blood.

        Exclusion Criteria:

          -  presence of severe or complicated malaria (WHO 2000),

          -  severe concomitant pathology or one that needs a medical follow-up incompatible with
             the study,

          -  allergic to one of the drugs involved in this study,

          -  pregnant (reported pregnancy, detected clinically or with the β HCG test),

          -  use of one of the anti-malaria drugs involved in this study during 28 days preceding
             inclusion.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Issaka Sagara, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Bamako, Mali</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Wilfred F Mbacham, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Yaoundé, Cameroon</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ishag A Adam, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Khartoum, Sudan</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stephen Rulisa, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kigali Central University Hospital, Rwanda</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cameroon Baptist Convention Clinic of Biyem-Assi</name>
      <address>
        <city>Yaounde</city>
        <country>Cameroon</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Health centres of Samako, Kolle and Bancoumane</name>
      <address>
        <city>Bamako</city>
        <country>Mali</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Health centres Rwamagana and Muhima</name>
      <address>
        <city>Kigali</city>
        <country>Rwanda</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alhara Alola Health centre</name>
      <address>
        <city>New Halfa</city>
        <country>Sudan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Cameroon</country>
    <country>Mali</country>
    <country>Rwanda</country>
    <country>Sudan</country>
  </location_countries>
  <verification_date>June 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 8, 2007</study_first_submitted>
  <study_first_submitted_qc>June 8, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 11, 2007</study_first_posted>
  <last_update_submitted>March 25, 2008</last_update_submitted>
  <last_update_submitted_qc>March 25, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 26, 2008</last_update_posted>
  <keyword>Open randomized multi-centre clinical trial in Africa</keyword>
  <keyword>Uncomplicated P. falciparum malaria</keyword>
  <keyword>Artemisinin-based Combination Therapy</keyword>
  <keyword>Artesunate + sulfalene + pyrimethamine</keyword>
  <keyword>24 hour treatment</keyword>
  <keyword>Artemether + lumefantrine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria</mesh_term>
    <mesh_term>Malaria, Falciparum</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Artesunate</mesh_term>
    <mesh_term>Lumefantrine</mesh_term>
    <mesh_term>Artemether</mesh_term>
    <mesh_term>Pyrimethamine</mesh_term>
    <mesh_term>Artemisinins</mesh_term>
    <mesh_term>Artemether-lumefantrine combination</mesh_term>
    <mesh_term>Artemisinine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

